» Articles » PMID: 31576115

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2019 Oct 3
PMID 31576115
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy with ICS is not currently recommended, but may be considered in association with LABAs in patients with a history of exacerbations and elevated eosinophils in spite of appropriate treatment with long-acting bronchodilators. However, long-term use of ICS in combination therapy has been associated with adverse effects, even if widely used in routine management for decades. The available evidence suggests that ICS can be rationally discontinued in patients with stable disease and is not likely to have unfavorable effects on lung function, overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely accepted that ICS therapy should be limited to a small proportion of patients after careful assessment of the individual risk-benefit profile. Unfortunately, however, there are no international recommendations that provide specific guidance or a protocol for withdrawal of ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is proposed that can provide clinicians with a simple management scheme to guide the most appropriate therapy for management of COPD and use of ICS. In management of COPD, a highly personalized approach is advocated so that the most appropriate therapy for each individual patient can be selected.

Citing Articles

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain.

Garcia V, Vallejo-Aparicio L, Ismaila A, Sicras-Mainar A, Sicras-Navarro A, Gonzalez C Int J Chron Obstruct Pulmon Dis. 2022; 17:2161-2174.

PMID: 36101793 PMC: 9464437. DOI: 10.2147/COPD.S367708.


Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.

Magnussen H, Lucas S, Lapperre T, Quint J, Dandurand R, Roche N Respir Res. 2021; 22(1):25.

PMID: 33478491 PMC: 7818945. DOI: 10.1186/s12931-021-01615-0.

References
1.
Di Marco F, Santus P, Terraneo S, Peruzzi E, Muscianisi E, Ripellino C . Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. NPJ Prim Care Respir Med. 2017; 27(1):51. PMC: 5589801. DOI: 10.1038/s41533-017-0051-9. View

2.
Papi A, Kostikas K, Wedzicha J, Vogelmeier C, Roche N, Shen S . Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. Am J Respir Crit Care Med. 2017; 197(9):1223-1226. DOI: 10.1164/rccm.201709-1822LE. View

3.
Hargreave F, Dolovich J, Pizzichini E, Pizzichini M . Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1996; 153(5):1726-7. DOI: 10.1164/ajrccm.153.5.8630628. View

4.
Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P . Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014; 9:215-28. PMC: 3940646. DOI: 10.2147/COPD.S51592. View

5.
Cabrera C, Casanova C, Martin Y, Mirabal V, Sanchez M, Alvarez F . Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. Int J Chron Obstruct Pulmon Dis. 2016; 11:1217-22. PMC: 4907482. DOI: 10.2147/COPD.S100853. View